Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2020 Phase II study in mild to moderate Alzheimer's disease
jRCT2031240712Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ONO-2020 in Alzheimer's disease (AD) (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Incidence, severity, and type of treatment-emergent adverse events, Clinically abnormal findings in Columbia Suicide Severity Rating Scale and 1 more. Started Jun 2025; status: completed.
02
Drugs
ONO-2020
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240712.